Track market-moving stories before they get noisy

New York, New York--(Newsfile Corp. - July 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On June 8, 2026, Investing.com published an article entitled "Ensign Group stock tumbles after short seller report." The article stated that Ensign shares fell after "short seller Hunterbrook released a report alleging the nursing home operator's business model relies on inadequate patient care and gaming quality metrics." Further, the article stated that Hunterbrook "published findings from a five-month investigation claiming the company's profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates. The report alleges patients have suffered and died as a result."

On this news, Ensign's shares fell 8.15% on June 8, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306482

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On June 8, 2026, Investing.com published an article entitled "Ensign Group stock tumbles after short seller report." The article stated that Ensign shares fell after "short seller Hunterbrook released a report alleging the nursing home operator’s business model relies on inadequate patient care and gaming quality metrics." Further, the article stated that Hunterbrook "published findings from a five-month investigation claiming the company’s profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates. The report alleges patients have suffered and died as a result."

On this news, Ensign Group shares fell 8.15% on June 8, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- The Ensign Group (NASDAQ: ENSG) investors saw the price of their shares in the skilled nursing facilities (“SNFs”) provider tumble over 8% on June 8 and another 3% on June 11, 2026 after Hunterbrook Media and Muddy Waters Research, respectively, published highly critical reports questioning Ensign’s business practices.

In total, over $500 million of Ensign’s market capitalization has been wiped out since June 7, 2026, the day before the first of the two reports.

These developments have prompted national shareholder rights firm Hagens Berman to open an investigation into allegations within the two reports and whether Ensign may have violated the federal securities laws.

The firm encourages Ensign investors who suffered substantial losses to submit your losses now.

The Ensign Group (ENSG) Investigation:

The investigation is primarily focused on the propriety of Ensign’s disclosures about SNF acquisitions, regulatory compliance, and certain accounting matters.

In the past, Ensign repeatedly assured investors that “compliance and quality outcomes are precursors to outstanding financial performance” and “we strive to aggressively increase quality in every facility we acquire, and to adjust our overall policies to adapt to CMS’s changing criteria for the Five-Star Quality Rating System.”

But, on June 8, 2026, Hunterbrook published its report, contending in part that “Ensign’s profits can be traced to providing less care than its patients need – and less care than it is meant to provide based on the tax dollars it receives from the government.” In addition, the firm said that “[w]e found Ensign’s growth strategy is to buy struggling nursing homes – then cut staff at those facilities and bank the savings, all while claiming quality improves.”

Then, on June 11, 2026, Muddy Waters Research published its report, adding to Hunterbrook’s analysis. Muddy Waters sent investigators to 57 of Ensign’s SNFs and found “red flags consistent with rented” NHA licenses that enabled “Ensign to state the facilities have licensed Administrators when in fact these administrators are seldom on premise and do not substantively manage the facilities.”

The firm concluded that “this scheme, which could amount to fraud against states, Medicare, and Medicaid, is the pillar upon which Ensign’s acquisition strategy and margins is built[]” and “[u]nder the False Claims Act, if these practices have been in place for one year at ~20% of facilities, we estimate the violations carry theoretical sanctions in the billions of dollars.”

“Our investigation is focused on whether the analysts’ allegations are accurate and, if so, whether Ensign may have misled investors about its business practices and accounting,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Ensign and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the firm’s Ensign investigation, read more »

Whistleblowers: Persons with non-public information regarding Ensign should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Contact:
Reed Kathrein, 844-916-0895

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System trimmed its holdings in shares of The Ensign Group, Inc. (NASDAQ:ENSG – Free Report) by 7.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 134,667 shares of the company’s stock after selling 10,863 shares during the quarter. California Public Employees Retirement System owned 0.23% of The Ensign Group worth $27,135,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Mitsubishi UFJ Trust & Banking Corp increased its position in shares of The Ensign Group by 52.5% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 54,336 shares of the company’s stock valued at $9,465,000 after purchasing an additional 18,699 shares during the last quarter. Cypress Wealth Services LLC purchased a new position in shares of The Ensign Group in the 4th quarter worth about $1,508,000. SG Americas Securities LLC boosted its holdings in shares of The Ensign Group by 70.2% in the 4th quarter. SG Americas Securities LLC now owns 38,029 shares of the company’s stock worth $6,625,000 after buying an additional 15,683 shares during the last quarter. Fort Washington Investment Advisors Inc. OH grew its position in The Ensign Group by 8.4% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 163,131 shares of the company’s stock valued at $28,417,000 after buying an additional 12,602 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in The Ensign Group by 14.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 129,756 shares of the company’s stock valued at $22,567,000 after buying an additional 16,853 shares during the period. 96.12% of the stock is currently owned by institutional investors.

Insider Activity In other news, Director Barry M. Smith sold 700 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $164.28, for a total value of $114,996.00. Following the sale, the director owned 21,352 shares of the company’s stock, valued at $3,507,706.56. The trade was a 3.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets A number of research firms recently issued reports on ENSG. Truist Financial decreased their price objective on shares of The Ensign Group from $215.00 to $202.00 and set a “hold” rating for the company in a report on Tuesday, July 14th. Wall Street Zen raised shares of The Ensign Group from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Weiss Ratings downgraded shares of The Ensign Group from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 16th. Zacks Research lowered shares of The Ensign Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of The Ensign Group in a report on Tuesday, June 9th. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $213.50.

Get Our Latest Report on ENSG

The Ensign Group Stock Down 0.7% ENSG stock opened at $170.87 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.56 and a current ratio of 1.56. The company has a market capitalization of $9.99 billion, a price-to-earnings ratio of 27.83, a PEG ratio of 1.68 and a beta of 0.69. The Ensign Group, Inc. has a fifty-two week low of $134.79 and a fifty-two week high of $218.00. The stock has a fifty day moving average of $165.80 and a 200-day moving average of $184.01.

The Ensign Group (NASDAQ:ENSG – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $1.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.06. The Ensign Group had a return on equity of 16.78% and a net margin of 6.89%.The business had revenue of $1.39 billion for the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the previous year, the business posted $1.52 EPS. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. The Ensign Group has set its FY 2026 guidance at 7.480-7.620 EPS. As a group, equities research analysts predict that The Ensign Group, Inc. will post 6.82 earnings per share for the current year.

The Ensign Group Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.065 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $0.26 annualized dividend and a dividend yield of 0.2%. The Ensign Group’s dividend payout ratio (DPR) is presently 4.23%.

About The Ensign Group (Free Report)

The Ensign Group, Inc is a diversified provider of post-acute healthcare services in the United States, operating a network of skilled nursing, assisted living, independent living, home health and hospice care centers. The company’s model emphasizes integrated care by employing multidisciplinary teams—including nursing staff, therapists and physicians—to deliver personalized rehabilitation and long-term care services for seniors and other patients recovering from injury, illness or surgery.

Through its owned and managed centers, The Ensign Group offers a broad spectrum of rehabilitation services such as physical, occupational and speech therapy.

Featured Articles Five stocks we like better than The Ensign Group Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding ENSG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Ensign Group, Inc. (NASDAQ:ENSG – Free Report).

Receive News & Ratings for The Ensign Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Ensign Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDimensional Fund Advisors LP Acquires 213,051 Shares of Aon plc $AON

NEXT HEADLINE »Dimensional Fund Advisors LP Acquires 834,885 Shares of Carnival Corporation $CCL

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The Ensign Group, Inc. (NASDAQ:ENSG) for potential securities fraud after significant stock drops.

If you invested in Ensign, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.

Key Details of the Ensign ($ENSG) Class Action Investigation:

Investigation Overview: Securities fraud relating to Ensign’s misrepresentations about care quality at the company’s nursing facilities, as well as Ensign’s growth, margins, and regulatory complianceStock Declines: June 8, 2026 – 8.2% Stock Drop; June 10, 2027 – 3% Stock DropAction: Contact BFA Law to discuss your rights Why is Ensign Being Investigated for Securities Fraud?

Ensign is a healthcare services company that operates skilled nursing, senior living, and rehabilitative care facilities through a network of affiliated providers. Ensign relies heavily on Medicare and Medicaid reimbursements, making government funding and regulatory compliance central to Ensign’s business model.

BFA is investigating whether Ensign misled investors about the quality of care at its facilities, as well as Ensign’s growth, margins, and regulatory compliance.

Why did Ensign’s Stock Drop?

On June 8, 2026, Hunterbrook Capital published a research report titled “Ensign: The Nursing Home Empire Built on Fatal Neglect” based on a five month investigation that alleged “Ensign’s profits can be traced to providing less care than its patients need – and less care than it is meant to provide based on the tax dollars it receives from the government.” According to Hunterbrook, Ensign padded its profit margin by understaffing its facilities while routing Medicare and Medicaid payments to affiliate entities owned or controlled by Ensign.

This news caused the price of Ensign stock to decline $13.88 per share, or 8.2%, from a closing price of $170.30 per share on June 5, 2026, to $156.42 per share on June 8, 2026.

On June 11, 2026, Muddy Waters Research published a research report titled “Ensign: Deceiving the Government at Estimated ~20% of Facilities” which alleged that Ensign “rents” required nursing-home administrator licenses from off-site administrators that do not actually oversee its facilities to create the appearance of regulatory compliance. According to Muddy Waters, genuine regulatory compliance would significantly reduce Ensign’s profitability.

On this news, the price of Ensign stock declined $4.52 per share, or 3%, from a closing price of $151.65 per share on June 10, 2026, to $147.13 per share on June 11, 2026.

Click here for more information: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.

What Can You Do?

If you invested in Ensign, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/ensign-class-action-lawsuit

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/ensign-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

So What: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On June 8, 2026, Investing.com published an article entitled "Ensign Group stock tumbles after short seller report." The article stated that Ensign shares fell after "short seller Hunterbrook released a report alleging the nursing home operator's business model relies on inadequate patient care and gaming quality metrics." Further, the article stated that Hunterbrook "published findings from a five-month investigation claiming the company's profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates. The report alleges patients have suffered and died as a result."

On this news, Ensign Group's shares fell 8.15% on June 8, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Posted by Defense World Staff on Jul 21st, 2026

Allspring Global Investments Holdings LLC lowered its holdings in shares of The Ensign Group, Inc. (NASDAQ:ENSG – Free Report) by 10.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 115,803 shares of the company’s stock after selling 13,953 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.20% of The Ensign Group worth $23,172,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of The Ensign Group by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 161,946 shares of the company’s stock worth $20,956,000 after purchasing an additional 14,590 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in The Ensign Group by 150.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 383 shares of the company’s stock worth $50,000 after acquiring an additional 230 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of The Ensign Group by 65.9% during the second quarter. EverSource Wealth Advisors LLC now owns 536 shares of the company’s stock worth $83,000 after acquiring an additional 213 shares during the period. Amundi increased its position in shares of The Ensign Group by 480,216.7% during the second quarter. Amundi now owns 57,638 shares of the company’s stock worth $8,583,000 after acquiring an additional 57,626 shares during the period. Finally, Brown Advisory Inc. increased its position in shares of The Ensign Group by 26.1% during the second quarter. Brown Advisory Inc. now owns 2,037 shares of the company’s stock worth $314,000 after acquiring an additional 421 shares during the period. Institutional investors own 96.12% of the company’s stock.

Insider Buying and Selling at The Ensign Group In related news, Director Barry M. Smith sold 700 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $164.28, for a total transaction of $114,996.00. Following the sale, the director owned 21,352 shares of the company’s stock, valued at $3,507,706.56. This trade represents a 3.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades A number of analysts recently issued reports on the company. Truist Financial lowered their price target on The Ensign Group from $215.00 to $202.00 and set a “hold” rating for the company in a report on Tuesday, July 14th. Wall Street Zen upgraded The Ensign Group from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Weiss Ratings lowered The Ensign Group from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 16th. Royal Bank Of Canada reiterated an “outperform” rating on shares of The Ensign Group in a report on Tuesday, June 9th. Finally, Zacks Research downgraded The Ensign Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $213.50.

Check Out Our Latest Research Report on ENSG

The Ensign Group Price Performance NASDAQ ENSG opened at $172.04 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.56 and a current ratio of 1.56. The firm’s 50 day moving average price is $165.91 and its 200-day moving average price is $184.03. The Ensign Group, Inc. has a 52-week low of $134.79 and a 52-week high of $218.00. The company has a market cap of $10.05 billion, a PE ratio of 28.02, a P/E/G ratio of 1.68 and a beta of 0.69.

The Ensign Group (NASDAQ:ENSG – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported $1.85 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.06. The company had revenue of $1.39 billion during the quarter, compared to the consensus estimate of $1.40 billion. The Ensign Group had a net margin of 6.89% and a return on equity of 16.78%. The Ensign Group’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.52 earnings per share. The Ensign Group has set its FY 2026 guidance at 7.480-7.620 EPS. Sell-side analysts forecast that The Ensign Group, Inc. will post 6.82 EPS for the current fiscal year.

The Ensign Group Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.065 dividend. This represents a $0.26 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Tuesday, June 30th. The Ensign Group’s payout ratio is presently 4.23%.

The Ensign Group Profile (Free Report)

The Ensign Group, Inc is a diversified provider of post-acute healthcare services in the United States, operating a network of skilled nursing, assisted living, independent living, home health and hospice care centers. The company’s model emphasizes integrated care by employing multidisciplinary teams—including nursing staff, therapists and physicians—to deliver personalized rehabilitation and long-term care services for seniors and other patients recovering from injury, illness or surgery.

Through its owned and managed centers, The Ensign Group offers a broad spectrum of rehabilitation services such as physical, occupational and speech therapy.

Featured Articles Five stocks we like better than The Ensign Group The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ENSG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Ensign Group, Inc. (NASDAQ:ENSG – Free Report).

Receive News & Ratings for The Ensign Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Ensign Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAllspring Global Investments Holdings LLC Sells 14,398 Shares of Entergy Corporation $ETR

NEXT HEADLINE »Allspring Global Investments Holdings LLC Buys 148,067 Shares of Levi Strauss & Co. $LEVI

New York, New York--(Newsfile Corp. - July 20, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against The Ensign Group, Inc. ("Ensign" or the "Company") (NASDAQ: ENSG).

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

If you are an Ensign investor and have suffered losses, or if you have information that could assist in the Ensign investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

On June 8, 2026, Hunterbrook Media published a report entitled "Ensign: The Nursing Home Empire Built On Fatal Neglect." The report alleges that "Ensign's business model relies on delivering inadequate care to patients while gaming data on quality, according to Hunterbrook's five-month investigation." The report further alleges "[f]ormer employees in different states described systematic misrepresentations."

Following this news, the price of Ensign stock fell $13.88 per share, or 8.15%, to close at $156.42 per share on June 8, 2026.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this investigation, please contact:

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/the-ensign-group-inc-class-action-alert-learn-more-now/

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305766

Source: Kaplan Fox & Kilsheimer LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating The Ensign Group (NASDAQ: ENSG) (“Ensign” or the “Company”) for potential violations of the federal securities laws.

On June 8, 2026, Hunterbrook published a detailed short-seller report alleging that the company engaged in systemic quality-measure gaming, falsified care-quality data, and improper related-party billing across its skilled nursing operations. Following this news, the price of Ensign stock fell significantly, causing millions of dollars in shareholder losses.

Then, on June 11, 2026, Muddy Waters Research published a short report on Ensign Group, alleging possible Medicare and Medicaid fraud via a scheme to rent licenses of administrators of skilled nursing facilities who are not actually managing the facilities, potentially in violation of the False Claims Act. This news caused the price of Ensign stock to drop even further.

“Our investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,” said Andrea Farah, Lowey Dannenberg, P.C., Partner and Head of the firm’s securities practice.

If you suffered a loss in Ensign securities and wish to participate, check your eligibility through Lowey’s case management platform, https://claimmagic.com/cases/the-ensign-group. Alternatively, you can contact our attorneys Andrea Farah ([email protected]) at (914)733-7256 or Vincent R. Cappucci Jr. ([email protected]) at (914)733-7278.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

Attorney Advertising

Contact

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email:  [email protected]

BFA Law is investigating whether Ensign committed securities fraud by making false and misleading statements to investors regarding the quality of care at its nursing facilities, the sustainability of its growth and profit margins, and its regulatory compliance.

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The Ensign Group, Inc. (NASDAQ:ENSG) for potential securities fraud after significant stock drops.

BFA Law is investigating whether Ensign committed securities fraud by making false and misleading statements to investors regarding the quality of care at its nursing facilities, the sustainability of its growth and profit margins, and its compliance.

ShareIf you invested in Ensign, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.

Key Details of the Ensign ($ENSG) Class Action Investigation:

Investigation Overview: Securities fraud relating to Ensign’s misrepresentations about care quality at the company’s nursing facilities, as well as Ensign’s growth, margins, and regulatory complianceStock Declines: June 8, 2026 – 8.2% Stock Drop; June 10, 2027 – 3% Stock DropAction: Contact BFA Law to discuss your rightsWhy is Ensign Being Investigated for Securities Fraud?

Ensign is a healthcare services company that operates skilled nursing, senior living, and rehabilitative care facilities through a network of affiliated providers. Ensign relies heavily on Medicare and Medicaid reimbursements, making government funding and regulatory compliance central to Ensign’s business model.

BFA is investigating whether Ensign misled investors about the quality of care at its facilities, as well as Ensign’s growth, margins, and regulatory compliance.

Why did Ensign’s Stock Drop?

On June 8, 2026, Hunterbrook Capital published a research report titled “Ensign: The Nursing Home Empire Built on Fatal Neglect” based on a five month investigation that alleged “Ensign’s profits can be traced to providing less care than its patients need – and less care than it is meant to provide based on the tax dollars it receives from the government.” According to Hunterbrook, Ensign padded its profit margin by understaffing its facilities while routing Medicare and Medicaid payments to affiliate entities owned or controlled by Ensign.

This news caused the price of Ensign stock to decline $13.88 per share, or 8.2%, from a closing price of $170.30 per share on June 5, 2026, to $156.42 per share on June 8, 2026.

On June 11, 2026, Muddy Waters Research published a research report titled “Ensign: Deceiving the Government at Estimated ~20% of Facilities” which alleged that Ensign “rents” required nursing-home administrator licenses from off-site administrators that do not actually oversee its facilities to create the appearance of regulatory compliance. According to Muddy Waters, genuine regulatory compliance would significantly reduce Ensign’s profitability.

On this news, the price of Ensign stock declined $4.52 per share, or 3%, from a closing price of $151.65 per share on June 10, 2026, to $147.13 per share on June 11, 2026.

Click here for more information: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.

What Can You Do?

If you invested in Ensign, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/ensign-class-action-lawsuit

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/ensign-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

If you purchased or acquired stock in Ensign and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.

Click here to participate in the action.

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against The Ensign Group, Inc. (“Ensign” or the “Company”) (NASDAQ:ENSG) on behalf of Ensign stockholders. Our investigation concerns whether Ensign has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details:

On June 8, 2026, Hunterbrook published a short report alleging that Ensign Group's business model relies on inadequate patient care and gaming quality metrics. The Hunterbrook report further alleges that Ensign Group's profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates, and that patients have suffered and died as a result.
Following publication of the Hunterbrook report, Ensign Group's stock price fell $13.88 per share, or 8.15%, to close at $156.42 per share on June 8, 2026. Next Steps:

If you purchased or otherwise acquired Ensign shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On June 8, 2026, Investing.com published an article entitled "Ensign Group stock tumbles after short seller report." The article stated that Ensign shares fell after "short seller Hunterbrook released a report alleging the nursing home operator’s business model relies on inadequate patient care and gaming quality metrics." Further, the article stated that Hunterbrook "published findings from a five-month investigation claiming the company’s profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates. The report alleges patients have suffered and died as a result."

On this news, Ensign Group shares fell 8.15% on June 8, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

So What: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On June 8, 2026, Investing.com published an article entitled "Ensign Group stock tumbles after short seller report." The article stated that Ensign shares fell after "short seller Hunterbrook released a report alleging the nursing home operator's business model relies on inadequate patient care and gaming quality metrics." Further, the article stated that Hunterbrook "published findings from a five-month investigation claiming the company's profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates. The report alleges patients have suffered and died as a result."

On this news, Ensign Group's shares fell 8.15% on June 8, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Also from this source

SAN DIEGO, July 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of United States federal securities laws involving The Ensign Group, Inc. (NASDAQ: ENSG).

If you any have information that could assist in the Ensign investigation or if you are an Ensign investor who suffered a loss and would like to learn more, you may provide your information here:

https://www.rgrdlaw.com/cases-the-ensign-group-inc-investigation-ensg.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

THE COMPANY: Ensign provides skilled nursing, senior living, and rehabilitative services.

THE REVELATION: On June 11, 2026, Muddy Waters Research published a report titled “Ensign: Deceiving the Government at Estimated ~20% of Facilities: Multi-Billion Dollar Potential Liability, Margins and Acquisitions that Cannot be Sustained Without Significant Ongoing Misconduct.” On this news, the price of Ensign stock fell.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.

Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        Ken Dolitsky
        Michael Albert
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800/851-7783
        [email protected]

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Ensign Group, Inc. ("Ensign Group" or the "Company") (NASDAQ: ENSG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Ensign Group and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On June 8, 2026, Hunterbrook published a short report alleging that Ensign Group's business model relies on inadequate patient care and gaming quality metrics. The Hunterbrook report further alleges that Ensign Group's profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates, and that patients have suffered and died as a result. 

Following publication of the Hunterbrook report, Ensign Group's stock price fell $13.88 per share, or 8.15%, to close at $156.42 per share on June 8, 2026. 

Then, on June 11, 2026, Muddy Waters Research published a short report on Ensign Group, alleging possible Medicare and Medicaid fraud via a scheme to rent licenses of administrators of skilled nursing facilities who are not actually managing the facilities, potentially in violation of the False Claims Act.

Following publication of the Muddy Waters report, Ensign's stock price fell $4.52 per share, or 2.98%, to close at $147.13 per share on June 11, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

New York, New York--(Newsfile Corp. - July 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On June 8, 2026, Investing.com published an article entitled "Ensign Group stock tumbles after short seller report." The article stated that Ensign shares fell after "short seller Hunterbrook released a report alleging the nursing home operator's business model relies on inadequate patient care and gaming quality metrics." Further, the article stated that Hunterbrook "published findings from a five-month investigation claiming the company's profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates. The report alleges patients have suffered and died as a result."

On this news, Ensign's shares fell 8.15% on June 8, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304513

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

SAN DIEGO--(BUSINESS WIRE)---- $ENSG #ENSG--Robbins Geller is investigating potential violations of the federal securities laws by Ensign.

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Ensign Group, Inc. (“Ensign Group” or the “Company”) (NASDAQ: ENSG).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Ensign Group and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On June 8, 2026, Hunterbrook published a short report alleging that Ensign Group’s business model relies on inadequate patient care and gaming quality metrics.  The Hunterbrook report further alleges that Ensign Group’s profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates, and that patients have suffered and died as a result. 

Following publication of the Hunterbrook report, Ensign Group’s stock price fell $13.88 per share, or 8.15%, to close at $156.42 per share on June 8, 2026. 

Then, on June 11, 2026, Muddy Waters Research published a short report on Ensign Group, alleging possible Medicare and Medicaid fraud via a scheme to rent licenses of administrators of skilled nursing facilities who are not actually managing the facilities, potentially in violation of the False Claims Act.   

Following publication of the Muddy Waters report, Ensign’s stock price fell $4.52 per share, or 2.98%, to close at $147.13 per share on June 11, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating The Ensign Group (NASDAQ: ENSG) (“Ensign” or the “Company”) for potential violations of the federal securities laws.

On June 8, 2026, Hunterbrook published a detailed short-seller report alleging that the company engaged in systemic quality-measure gaming, falsified care-quality data, and improper related-party billing across its skilled nursing operations. Following this news, the price of Ensign stock fell significantly, causing millions of dollars in shareholder losses.

Then, on June 11, 2026, Muddy Waters Research published a short report on Ensign Group, alleging possible Medicare and Medicaid fraud via a scheme to rent licenses of administrators of skilled nursing facilities who are not actually managing the facilities, potentially in violation of the False Claims Act. This news caused the price of Ensign stock to drop even further.

“Our investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,” said Andrea Farah, Lowey Dannenberg, P.C., Partner and Head of the firm’s securities practice.

If you suffered a loss in Ensign securities and wish to participate, check your eligibility through Lowey’s case management platform, https://claimmagic.com/cases/the-ensign-group. Alternatively, you can contact our attorneys Andrea Farah ([email protected]) at (914)733-7256 or Vincent R. Cappucci Jr. ([email protected]) at (914)733-7278.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

Attorney Advertising

Contact

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email:  [email protected]

NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The Ensign Group, Inc. (NASDAQ:ENSG) for potential securities fraud after significant stock drops.

If you invested in Ensign, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.

Key Details of the Ensign ($ENSG) Class Action Investigation:

Investigation Overview: Securities fraud relating to Ensign’s misrepresentations about care quality at the company’s nursing facilities, as well as Ensign’s growth, margins, and regulatory complianceStock Declines: June 8, 2026 – 8.2% Stock Drop; June 10, 2027 – 3% Stock DropAction: Contact BFA Law to discuss your rights
Why is Ensign Being Investigated for Securities Fraud?

Ensign is a healthcare services company that operates skilled nursing, senior living, and rehabilitative care facilities through a network of affiliated providers. Ensign relies heavily on Medicare and Medicaid reimbursements, making government funding and regulatory compliance central to Ensign’s business model.

BFA is investigating whether Ensign misled investors about the quality of care at its facilities, as well as Ensign’s growth, margins, and regulatory compliance.

Why did Ensign’s Stock Drop?

On June 8, 2026, Hunterbrook Capital published a research report titled “Ensign: The Nursing Home Empire Built on Fatal Neglect” based on a five month investigation that alleged “Ensign’s profits can be traced to providing less care than its patients need – and less care than it is meant to provide based on the tax dollars it receives from the government.” According to Hunterbrook, Ensign padded its profit margin by understaffing its facilities while routing Medicare and Medicaid payments to affiliate entities owned or controlled by Ensign.

This news caused the price of Ensign stock to decline $13.88 per share, or 8.2%, from a closing price of $170.30 per share on June 5, 2026, to $156.42 per share on June 8, 2026.

On June 11, 2026, Muddy Waters Research published a research report titled “Ensign: Deceiving the Government at Estimated ~20% of Facilities” which alleged that Ensign “rents” required nursing-home administrator licenses from off-site administrators that do not actually oversee its facilities to create the appearance of regulatory compliance. According to Muddy Waters, genuine regulatory compliance would significantly reduce Ensign’s profitability.

On this news, the price of Ensign stock declined $4.52 per share, or 3%, from a closing price of $151.65 per share on June 10, 2026, to $147.13 per share on June 11, 2026.

Click here for more information: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.

What Can You Do?

If you invested in Ensign, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/ensign-class-action-lawsuit

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/ensign-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Ensign Group (ENSG - Free Report) Founded in 1999 and headquartered in San Juan Capistrano, CA, The Ensign Group Inc. provides healthcare services in the post-acute care continuum, urgent care center and mobile ancillary segments in the United States.

ENSG is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. ENSG has a Growth Style Score of A, forecasting year-over-year earnings growth of 14.6% for the current fiscal year.

For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $7.53 per share. ENSG boasts an average earnings surprise of +3.4%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, ENSG should be on investors' short list.

SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving The Ensign Group, Inc. (NASDAQ: ENSG).

If you any have information that could assist in the Ensign investigation or if you are an Ensign investor who suffered a loss and would like to learn more, you may provide your information here:

https://www.rgrdlaw.com/cases-the-ensign-group-inc-investigation-ensg.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

THE COMPANY: Ensign provides skilled nursing, senior living, and rehabilitative services.

THE REVELATION: On June 11, 2026, Muddy Waters Research published a report titled “Ensign: Deceiving the Government at Estimated ~20% of Facilities: Multi-Billion Dollar Potential Liability, Margins and Acquisitions that Cannot be Sustained Without Significant Ongoing Misconduct.” On this news, the price of Ensign stock fell.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        Ken Dolitsky
        Michael Albert
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800/851-7783
        [email protected]

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Ensign Group, Inc. ("Ensign Group" or the "Company") (NASDAQ: ENSG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Ensign Group and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On June 8, 2026, Hunterbrook published a short report alleging that Ensign Group's business model relies on inadequate patient care and gaming quality metrics. The Hunterbrook report further alleges that Ensign Group's profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates, and that patients have suffered and died as a result. 

Following publication of the Hunterbrook report, Ensign Group's stock price fell $13.88 per share, or 8.15%, to close at $156.42 per share on June 8, 2026. 

Then, on June 11, 2026, Muddy Waters Research published a short report on Ensign Group, alleging possible Medicare and Medicaid fraud via a scheme to rent licenses of administrators of skilled nursing facilities who are not actually managing the facilities, potentially in violation of the False Claims Act.

Following publication of the Muddy Waters report, Ensign's stock price fell $4.52 per share, or 2.98%, to close at $147.13 per share on June 11, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- The Ensign Group (NASDAQ: ENSG) investors saw the price of their shares in the skilled nursing facilities ("SNFs") provider tumble over 8% on June 8 and another 3% on June 11, 2026 after Hunterbrook Media and Muddy Waters Research, respectively, published highly critical reports questioning Ensign's business practices.

In total, over $500 million of Ensign's market capitalization has been wiped out since June 7, 2026, the day before the first of the two reports.

These developments have prompted national shareholder rights firm Hagens Berman to open an investigation into allegations within the two reports and whether Ensign may have violated the federal securities laws.

The firm encourages Ensign investors who suffered substantial losses to submit your losses now.

Visit: www.hbsslaw.com/investor-fraud/ensg
Contact the Firm Now: [email protected]
                                        844-916-0895

The Ensign Group (ENSG) Investigation:

The investigation is primarily focused on the propriety of Ensign's disclosures about SNF acquisitions, regulatory compliance, and certain accounting matters.

In the past, Ensign repeatedly assured investors that "compliance and quality outcomes are precursors to outstanding financial performance" and "we strive to aggressively increase quality in every facility we acquire, and to adjust our overall policies to adapt to CMS's changing criteria for the Five-Star Quality Rating System."

But, on June 8, 2026, Hunterbrook published its report, contending in part that "Ensign's profits can be traced to providing less care than its patients need – and less care than it is meant to provide based on the tax dollars it receives from the government." In addition, the firm said that "[w]e found Ensign's growth strategy is to buy struggling nursing homes – then cut staff at those facilities and bank the savings, all while claiming quality improves."

Then, on June 11, 2026, Muddy Waters Research published its report, adding to Hunterbrook's analysis. Muddy Waters sent investigators to 57 of Ensign's SNFs and found "red flags consistent with rented" NHA licenses that enabled "Ensign to state the facilities have licensed Administrators when in fact these administrators are seldom on premise and do not substantively manage the facilities."

The firm concluded that "this scheme, which could amount to fraud against states, Medicare, and Medicaid, is the pillar upon which Ensign's acquisition strategy and margins is built[]" and "[u]nder the False Claims Act, if these practices have been in place for one year at ~20% of facilities, we estimate the violations carry theoretical sanctions in the billions of dollars." 

"Our investigation is focused on whether the analysts' allegations are accurate and, if so, whether Ensign may have misled investors about its business practices and accounting," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in Ensign and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

If you'd like more information and answers to other frequently asked questions about the firm's Ensign investigation, read more »

Whistleblowers: Persons with non-public information regarding Ensign should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The Ensign Group, Inc. (NASDAQ:ENSG) for potential securities fraud after significant stock drops.

If you invested in Ensign, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.

Key Details of the Ensign ($ENSG) Class Action Investigation:

Investigation Overview: Securities fraud relating to Ensign’s misrepresentations about care quality at the company’s nursing facilities, as well as Ensign’s growth, margins, and regulatory complianceStock Declines: June 8, 2026 – 8.2% Stock Drop; June 10, 2027 – 3% Stock DropAction: Contact BFA Law to discuss your rights Why is Ensign Being Investigated for Securities Fraud?

Ensign is a healthcare services company that operates skilled nursing, senior living, and rehabilitative care facilities through a network of affiliated providers. Ensign relies heavily on Medicare and Medicaid reimbursements, making government funding and regulatory compliance central to Ensign’s business model.

BFA is investigating whether Ensign misled investors about the quality of care at its facilities, as well as Ensign’s growth, margins, and regulatory compliance.

Why did Ensign’s Stock Drop?

On June 8, 2026, Hunterbrook Capital published a research report titled “Ensign: The Nursing Home Empire Built on Fatal Neglect” based on a five month investigation that alleged “Ensign’s profits can be traced to providing less care than its patients need – and less care than it is meant to provide based on the tax dollars it receives from the government.” According to Hunterbrook, Ensign padded its profit margin by understaffing its facilities while routing Medicare and Medicaid payments to affiliate entities owned or controlled by Ensign.

This news caused the price of Ensign stock to decline $13.88 per share, or 8.2%, from a closing price of $170.30 per share on June 5, 2026, to $156.42 per share on June 8, 2026.

On June 11, 2026, Muddy Waters Research published a research report titled “Ensign: Deceiving the Government at Estimated ~20% of Facilities” which alleged that Ensign “rents” required nursing-home administrator licenses from off-site administrators that do not actually oversee its facilities to create the appearance of regulatory compliance. According to Muddy Waters, genuine regulatory compliance would significantly reduce Ensign’s profitability.

On this news, the price of Ensign stock declined $4.52 per share, or 3%, from a closing price of $151.65 per share on June 10, 2026, to $147.13 per share on June 11, 2026.

Click here for more information: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.

What Can You Do?

If you invested in Ensign, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/ensign-class-action-lawsuit

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/ensign-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.